Comparative pharmaceutico-analytical study of two types of kanta loha bhasmas and their clinical efficacy in the management of type 2 diabetes

Comparative pharmaceutico-analytical study of two types of kanta loha bhasmas and their clinical efficacy in the management of madhumeha(type 2 diabetes) - type 2 diabetes

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2020/05/025358

Enrollment

Registered

2020-05-26

Start date

Unknown

Completion date

Unknown

Last updated

2023-12-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Kanta loha bhasma: Each patient will receive 1 tablet made of 250mg Kanta loha bhasma +65mg Triphala Ghana, twice a day (15 mins before meal) duration 8 weeks Control Intervention1: Kan

Eligibility

Inclusion criteria

Inclusion criteria: .Known patient of type 2 diabetes and also preliminary diagnosed patients .patients having fasting blood sugar >126mg/dl and/or PPBS >200mg/dl or elevated HbA1C

Exclusion criteria

Exclusion criteria: .Patients of any other severe illnes .Patients having diabetic non healing wound,systemic infection,malignant and accelarated hypertensive .Patients having severe anaemia Hb% .Patients with diabetic ketoacidosis,end stage renal disease

Design outcomes

Primary

Measure	Time frame
Relief in signs and symptoms of diabetesTimepoint: 8 weeks	—

Secondary

Measure	Time frame
Improvement of health condition and also relief in signs and symptoms of diabetesTimepoint: 1.5 year	—

Countries

India

Contacts

Public ContactDr Prashant Bedarkar

Institute for Postgraduate Teaching and Research in Ayurveda

drprashantbedarkar@gmail.com8128217370

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026